Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

7.3K
The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
7.3K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

8.7K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

7.2K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.2K
Signal Transduction: Overview01:26

Signal Transduction: Overview

8.2K
Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
8.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lymph node stromal topology as a hidden regulator of breast cancer outcome: commentary on reticular network analysis<sup>†</sup>.

The Journal of pathology·2026
Same author

Microglia Rank signaling regulates GnRH neuronal function and the hypothalamic-pituitary-gonadal axis.

Science (New York, N.Y.)·2026
Same author

Rank signaling drives basal cell-lineage infidelity leading to mammary tumorigenesis.

Nature communications·2026
Same author

Glucose deprivation drives LIF-dependent lung cancer.

Nature metabolism·2026
Same author

Indole-3-carbinol is an inhibitor of K<sub>V</sub>1.3 potassium voltage-gated channel activity in chronic lymphocytic leukemia cells.

European journal of pharmacology·2025
Same author

RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response.

Molecular cancer therapeutics·2025

Related Experiment Video

Updated: Jun 1, 2025

An Ex vivo Model to Study Hormone Action in the Human Breast
12:31

An Ex vivo Model to Study Hormone Action in the Human Breast

Published on: January 8, 2015

11.4K

RANK/RANKL Signaling Pathway in Breast Development and Cancer.

Gema Pérez-Chacón1, Patricia G Santamaría1, Jaime Redondo-Pedraza1

  • 1Molecular Oncology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Advances in Experimental Medicine and Biology
|January 17, 2025
PubMed
Summary

Targeting the RANK pathway with denosumab shows promise for breast cancer prevention and treatment. Inhibiting RANKL may enhance tumor cell differentiation, boost immune response, and improve sensitivity to existing therapies.

Keywords:
Breast cancerDenosumabImmunotherapyMammary glandRANKRANKL

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.3K

Related Experiment Videos

Last Updated: Jun 1, 2025

An Ex vivo Model to Study Hormone Action in the Human Breast
12:31

An Ex vivo Model to Study Hormone Action in the Human Breast

Published on: January 8, 2015

11.4K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.3K

Area of Science:

  • Oncology
  • Immunology
  • Endocrinology

Background:

  • The RANK signaling pathway is implicated in mammary gland development and breast cancer initiation, progression, and metastasis.
  • RANK activation influences mammary cell proliferation, stem cell fate, and senescence, with its expression linked to poor prognosis in certain breast cancer subtypes.
  • RANK/RANKL also play roles in immune regulation within the tumor microenvironment, often promoting immunosuppression.

Purpose of the Study:

  • To discuss the preventive and therapeutic potential of targeting the RANK signaling pathway in breast cancer.
  • To explore the intrinsic and extrinsic effects of RANK signaling on tumor development.
  • To review clinical trials investigating denosumab for breast cancer.

Main Methods:

  • Review of existing literature on RANK pathway in breast cancer.
  • Analysis of the role of RANK/RANKL in tumor cell biology and the tumor immune microenvironment.
  • Description of ongoing and completed clinical trials involving denosumab.

Main Results:

  • RANKL inhibition can induce mammary tumor cell differentiation and stimulate an antitumor immune response.
  • Loss of RANK signaling can sensitize breast cancer cells to chemotherapy, targeted therapies (HER2, CDK4/6 inhibitors), and immunotherapy.
  • Denosumab is being evaluated in clinical trials for breast cancer prevention and treatment, including its immunomodulatory effects.

Conclusions:

  • Targeting the RANK pathway presents a promising strategy for both preventing and treating breast cancer.
  • Denosumab, an anti-RANKL drug, demonstrates potential in enhancing treatment efficacy and modulating the immune response against breast cancer.
  • Further clinical evaluation is ongoing to establish the full impact of RANKL inhibition in breast cancer management.